NASDAQ
86.39USD
+2.94 (+3.52%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
32.6B
P/E
—
EPS
—
Beta
1.45
52W range
54.11-87.6199
Day range
83.51–87.62
Open
85.30
Prev close
83.45
Volume
4.1M
Avg volume
5.7M
Dividend
0.00
IPO
2005-04-14
https://247wallst.com/investing/2026/08/03/abbott-laboratories-lost-16-this-year-one-analyst-sees-35-gains-for-the-healthcare-giant/ · 8/3/2026+0.00
https://www.marketbeat.com/instant-alerts/dexcom-q2-earnings-call-highlights-2026-07-30/ · 7/30/2026+1.00
https://247wallst.com/investing/2026/07/16/what-investors-dont-understand-about-abbott-laboratories/ · 7/16/2026-0.30
https://www.businesswire.com/news/home/20260713940133/en/Dexcom-G7-15-Day-Receives-Health-Canada-Authorization-Extending-Wear-and-Continuity-for-Canadian-Adults-Living-with-Diabetes/ · 7/13/2026+0.80
https://seekingalpha.com/article/4919352-dexcom-the-growth-thesis-still-needs-to-be-proven · 7/2/2026-0.40
https://www.marketbeat.com/articles/3-non-pharma-firms-that-could-benefit-from-the-glp-1-trend/ · 6/20/2026+0.80
https://www.zacks.com/stock/news/2937978/abbott-s-cgm-growth-story-stays-intact-despite-q1-moderation?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2937978 · 6/16/2026+0.00
https://www.reuters.com/business/healthcare-pharmaceuticals/dexcoms-glucose-monitor-use-shows-benefit-non-insulin-diabetic-patients-study-2026-06-06/ · 6/6/2026+0.80
https://www.businesswire.com/news/home/20260606323066/en/Dexcom-CONNECT-Study-The-Most-Significant-Clinical-Study-Demonstrating-CGM-Benefits-for-People-with-Type-2-Diabetes-Not-Using-Insulin/ · 6/6/2026+0.80
https://www.reuters.com/legal/litigation/dexcom-warns-patients-stolen-glucose-sensors-hit-market-2026-05-26/ · 5/26/2026-0.40
https://seekingalpha.com/article/4908123-dexcom-a-medical-platform-play-gaining-from-ai-not-disrupted-by-it · 5/22/2026+0.90
https://www.marketbeat.com/instant-alerts/dexcom-maps-g8-launch-coverage-expansion-and-double-digit-growth-at-investor-day-2026-05-16/ · 5/16/2026+0.90
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
